UNSPSC 51293202: Phenelzine

This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C8H12N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O408N561GF, chemically known as hydrazine, phenethyl-, monohydrochloride but generally known as phenelzine, which bears US NIH Compound Identifier 3675. European Medicines Agency schedules Phenelzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09757MIG. The term PHENELZINE is an International Non-Proprietary Name.

UNSPSC 51293202 Phenelzine (Commodity) shows minimal relevant recent state and local procurement activity. The recent opportunities tagged to this code do not target phenelzine or its pharmaceutical class; instead, they involve naloxone procurement, therapeutic pharmacy program development, and generic multi-source pharmaceutical contracting through cooperative purchasing. State and local governments use this Commodity code to identify specific pharmaceutical products for health and human services delivery, but the three most recent posted solicitations align with broader pharmaceutical procurement frameworks rather than phenelzine-specific buys.

The issuing bodies include a county health department (Seminole County, Florida), a state HHS agency (Texas Health and Human Services Commission), and a multi-state cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participant jurisdictions). The geographic activity spans Florida, Texas, and the upper Midwest, though the source does not indicate concentration under this code. No recent opportunities explicitly solicit phenelzine as a line item; the Seminole County IFB (due July 26, 2023) targets naloxone and drug deactivation systems; the Texas HHS RFI (due April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription programs; and the MMCAP RFP (due March 26, 2026) establishes cooperative contracts for generic multi-source pharmaceuticals and OTC products. The code shows no standout repeat buyers or strong activity signal at the commodity level for phenelzine specifically.